🧪 What’s the Anthem Biosciences IPO about?

• Issue Type & Size
  – A pure Offer For Sale (OFS) worth ₹3,395 crore (no fresh capital raised)—existing shareholders cashing out.
  – Promoters (Ganesh Sambasivam, K Ravindra Chandrappa) selling ₹350 crore each; PE investor True North’s Viridity Tone LLP offloading ~₹1,325 crore.
• Dates & Listing
  – Bidding: 14–16 July 2025; allotment on 17 July; listing expected 21 July on BSE & NSE.
• Price & Lots
  – Price band: ₹540–₹570 per share; minimum lot: 26 shares (≈₹14,820).
  – The IPO allocation is divided as follows: 50% reserved for Qualified Institutional Buyers (QIBs), 35% for retail individual investors, and the remaining 15% earmarked for Non-Institutional Investors (NIIs).

Why the market is keen

1. Strong subscription momentum
   – By midday Day 2, overall subscription stood at 2.08×.
   – Day 1 saw full retail quota nearly subscribed, NIIs at 1.04×, QIBs at 0.36×; mixed but improving.
2. Grey Market Premium (GMP)
   – Reports peg GMP around ₹105–130, suggesting ~20% listing gains

🏭 Business Overview: CRDMO with edge

• What they do
  – A Bengaluru-based Contract Research, Development & Manufacturing Organization (CRDMO) offering end-to-end services—from discovery through to manufacturing—for APIs, peptides, enzymes, biosimilars, probiotics, vitamins, etc.
• Facilities & Compliance
  – Two cGMP‑compliant plants operating in Karnataka; a third (Unit III) now active, and Unit IV (spread over 30 acres) in development.
  – Facilities approved by US FDA, ANVISA, TGA, PMDA with no FDA observations.
• Global Reach
  – Serving over 550 clients across 44+ countries, with >80% revenues from the US, EU & China.
  – Strategic US partner: DavosPharma (Portsmouth Technologies affiliate).
• Innovation & Supply Chain
  – Strong in fermentation-based APIs (probiotics, peptides) and green chemistry through automation and process controls.
  – <20% raw‑material dependency on China vs. 60–70% by peers—key advantage.

🔢 Anthem Biosciences IPO : Financial Highlights (FY25 vs FY24)

Patents & Projects: 196 ongoing projects; 8 patents granted; 24 pending

✅ Strengths

• Fully integrated CRDMO covering small molecules and biologics—rare among Indian peers .
• Advanced fermentation capabilities; Unit III expands capacity; Unit IV under construction.
• Quality compliance (cGMP + ISO + regulatory approvals) with automation and robust audit performance .
• Global reach with diversified client base and strategic partnerships.
• Healthy financials: strong profit margins, low debt, rapid revenue growth.

⚠️ Anthem Biosciences IPO : Risks & Considerations

• OFS-only nature: Company gains no fresh capital—OFS benefits shareholders, not expansion .
• Regulatory & geopolitical risk: Biotech sector faces government scrutiny, regulatory approvals, and global tensions.
• Valuation premium: P/E ~70× is rich; margin for error if growth slows.
• Market & execution: Success depends on converting API project pipeline and global demand retention.

📈 Outlook

• Listing gains likely: With GMP showing ~₹110, there’s potential for a 20%+ upside.
• Long-term play: If Anthem continues growth, expands Unit IV, and wins more global contracts, it could validate the premium valuation.
• Timing caution: Global and India IPO trends show sensitivity—any adverse market phase may impact listing performance.

🔍 Should you subscribe Anthem Biosciences IPO?

• Short‑term listing gain: The GMP suggests potential listing upside.
• Long‑term investor: Promising CRDMO play—but be mindful of valuation and lack of fresh capital inflows.
• Risk appetite: Good for investors comfortable with biotech exposure, global regulatory complexities, and richly priced assets.

🔚 Final Word

The Anthem Biosciences IPO offers a compelling blend of strong fundamentals and attractive listing prospects. However, its fully OFS nature, elevated valuation, and biotech sector risks require careful evaluation. If you believe in India’s rise as a global CRDMO hub—and trust Anthem’s integrated capabilities and growth roadmap—it presents a well-rounded opportunity.

Here’s a 100% unique and AdSense-safe FAQ section for the Anthem Biosciences Ltd. IPO, fully optimized for SEO and human readability:

📌 Frequently Asked Questions (FAQs) about Anthem Biosciences Ltd. IPO

❓ What is the Anthem Biosciences IPO date?

📅 The IPO opens on July 14, 2025, and closes on July 16, 2025. The shares are likely to be listed on July 21, 2025 on both NSE and BSE.

❓ What is the price band for Anthem Biosciences IPO?

💸 The IPO is priced in the range of ₹540 to ₹570 per share.

❓ What is the lot size for Anthem Biosciences IPO?

📦 A single lot consists of 26 equity shares. Investors need a minimum investment of around ₹14,820 to participate.

❓ Is this a fresh issue or Offer for Sale?

📝 It is a 100% Offer for Sale (OFS). No new shares are being issued—existing shareholders are selling part of their holdings.

❓ How are shares allocated in this IPO?

📊 The shares are distributed as follows:

• 50% for Qualified Institutional Buyers (QIBs)
• 35% for Retail Individual Investors (RIIs)
• 15% for Non-Institutional Investors (NIIs)

❓ What is the GMP (Grey Market Premium) of Anthem Biosciences IPO?

📈 The GMP has been reported in the range of ₹105 to ₹130, suggesting a potential listing gain of around 18–22% over the issue price.

❓ What does Anthem Biosciences Ltd. do?

🔬 Anthem Biosciences is a Contract Research, Development, and Manufacturing Organization (CRDMO). It offers end-to-end services for APIs, biologics, enzymes, peptides, and more. The company serves over 550 clients in 44+ countries.

❓ Is Anthem Biosciences IPO good for listing gains?

🚀 Based on current GMP trends and financial performance, listing gains are expected, but investors should evaluate market sentiment and risk appetite before subscribing.

❓ Does Anthem Biosciences follow regulatory and quality compliance?

✅ Yes, its facilities are cGMP-compliant and approved by US FDA, TGA, ANVISA, and other global regulators. This adds credibility to its global manufacturing standards.

❓ How has the company performed financially?

💰 Anthem Biosciences posted a 30% revenue growth in FY25, with profit after tax reaching ₹451 crore. It has low debt and strong margins, making it financially sound.